Diacetylmorphine, or heroin, may be a more effective treatment than methadone for people with relapsing chronic opioid dependence, according to a study published in the Canadian Medical Association Journal.
Diacetylmorphine, or heroin, may be a more effective treatment than methadone for people with relapsing chronic opioid dependence, according to a study published in the Canadian Medical Association Journal.
Aslam Anis, PhD, director of the Centre for Health Evaluation and Outcome Sciences at St. Paul’s Hospital in Vancouver, and colleagues, stated that studies have shown that diacetylmorphine is more effective than methadone maintenance treatment in keeping opioid-dependent patients in treatment; however, they noted that there are political challenges as well as concerns that the treatment could cost up to 10 times more than the conventional methadone therapy.
To assess the long-term cost-effectiveness of diacetylmorphine versus methadone maintenance treatment, the researchers extrapolated outcomes from the North American Opiate Medication Initiative using a mathematical model (semi-Markov).
The model aimed to capture the cycles of treatment, relapse, and abstinence observed in long-term observational studies of opioid-dependent individuals, the authors said, and considered time horizons of 1, 5, and 10 years as well as the lifetime to project costs and outcomes over the expected duration of treatment and its effects.
In each time horizon, the researchers found heroin to be the dominant strategy. Over a lifetime horizon, people receiving methadone lived 14.54 years on average following entry into the model, and they spent 8.79 years (60% of their remaining life) in treatment and 5.52 years in relapse. Those receiving methadone also gained an average 7.46 discounted quality-adjusted life-years (QALY) and generated a societal cost of $1.14 million.
Patients receiving the heroin lived 15.45 years on average, and they spent 10.41 years (67% of their remaining life) in treatment (2.34 years of which was in post-diacetylmorphine methadone treatment) and 4.05 years in relapse. They gained an average 7.92 discounted QALYs and generated a societal cost of $1.10 million.
“Our model indicated that diacetylmorphine would decrease societal costs, largely by reducing costs associated with crime, and would increase both the duration and quality of life of treatment recipients,” the authors concluded.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.